HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Astrup, A. S. Articles by Parving, H.-H. Search for Related Content PubMed PubMed Citation Articles by Astrup, A. S. Articles by Parving, H.-H. Social Bookmarking                What's this?

Cardiac Autonomic Neuropathy Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy

¹ Steno Diabetes Center, Gentofte, Denmark
² Rigshospitalet, Copenhagen, Denmark
³ Faculty of Health Science, Aarhus University, Aarhus, Denmark

Address correspondence and reprint requests to Anne Sofie Astrup, MD, Steno Diabetes Center, Niels Steensensvej 2, 2820 Gentofte, Denmark. E-mail: ansa{at}steno.dk

OBJECTIVE—Cardiac autonomic neuropathy (CAN) has been associated with a poor prognosis in patients with diabetes. Because CAN is common in patients with diabetic nephropathy, we evaluated the predictive value of CAN in type 1 diabetic patients with and without diabetic nephropathy.

RESEARCH DESIGN AND METHODS—In a prospective observational follow-up study, 197 type 1 diabetic patients with diabetic nephropathy and a matched group of 191 patients with long-standing type 1 diabetes and normoalbuminuria were followed for 10.1 years (range 0.0–10.3 years). At baseline, CAN was assessed by heart rate variation (HRV) during deep breathing. HRV was evaluated as a predictor of the primary end point: cardiovascular morbidity and mortality. As secondary end points, all-cause mortality and the influence of HRV on progression of diabetic nephropathy (decline in glomerular filtration rate [GFR]) was evaluated.

RESULTS—During the follow-up, 79 patients (40%) with nephropathy reached the combined primary end point vs. 19 patients (10%) with normoalbuminuria (log-rank test, P < 0.0001). The unadjusted hazard ratio (HR) for reaching the primary end point when having an abnormal HRV (10 bpm) measured at baseline compared with a normal HRV was 7.7 (range 1.9–31.5; P = 0.004) in patients with nephropathy. Similarly in the normoalbuminuric patients, the unadjusted HR was 4.4 (1.4–13.6; P = 0.009). In patients with nephropathy, abnormal HRV was significantly associated with fatal and nonfatal cardiovascular disease after adjustment for cardiovascular risk factors. The adjusted HR for reaching the primary end point in a patient with nephropathy and an abnormal HRV was 6.4 (1.5–26.3, P = 0.010), as compared with a normal HRV. The unadjusted HR for dying when having an abnormal HRV compared with a normal HRV was 3.3 (95% CI 1.0–10.7; P = 0.043) in patients with diabetic nephropathy. After adjustment for confounding factors, the impact of HRV on all-cause mortality in patients with nephropathy was no longer significant (P = 0.293). There was no relationship between abnormal HRV and rate of decline in GFR.

CONCLUSIONS—HRV is an independent risk factor for cardiovascular morbidity and mortality in type 1 diabetic patients with nephropathy.

Abbreviations: CAN, cardiac autonomic neuropathy • CVD, cardiovascular disease • GFR, glomerular filtration rate • HRV, heart rate variation

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. S. Astrup, W. Y. Kim, L. Tarnow, R. M. Botnar, C. Simonsen, L. Brix, L. Pietraszek, P. R. Hansen, W. J. Manning, and H.-H. Parving Relation of Left Ventricular Function, Mass, and Volume to NT-proBNP in Type 1 Diabetic Patients Diabetes Care, May 1, 2008; 31(5): 968 - 970. [Abstract] [Full Text] [PDF]

				G. Joseph, L. Tarnow, A. S. Astrup, T. K. Hansen, H.-H. Parving, A. Flyvbjerg, and J. Frystyk Plasma {alpha}-Defensin Is Associated with Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1470 - 1475. [Abstract] [Full Text] [PDF]

				J M Pappachan, J Sebastian, B C Bino, K Jayaprakash, K Vijayakumar, P Sujathan, and L A Adinegara Cardiac autonomic neuropathy in diabetes mellitus: prevalence, risk factors and utility of corrected QT interval in the ECG for its diagnosis Postgrad. Med. J., April 1, 2008; 84(990): 205 - 210. [Abstract] [Full Text] [PDF]

				D. Ziegler, C. P. Zentai, S. Perz, W. Rathmann, B. Haastert, A. Doring, C. Meisinger, and for the KORA Study Group Prediction of Mortality Using Measures of Cardiac Autonomic Dysfunction in the Diabetic and Nondiabetic Population: The MONICA/KORA Augsburg Cohort Study Diabetes Care, March 1, 2008; 31(3): 556 - 561. [Abstract] [Full Text] [PDF]

				G. A. Lanza, D. Pitocco, E. P. Navarese, A. Sestito, G. A. Sgueglia, A. Manto, F. Infusino, T. Musella, G. Ghirlanda, and F. Crea Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade Eur. Heart J., April 1, 2007; 28(7): 814 - 820. [Abstract] [Full Text] [PDF]

				A. I. Vinik and D. Ziegler Diabetic Cardiovascular Autonomic Neuropathy Circulation, January 23, 2007; 115(3): 387 - 397. [Full Text] [PDF]

				W. Y. Kim, A. S. Astrup, M. Stuber, L. Tarnow, E. Falk, R. M. Botnar, C. Simonsen, L. Pietraszek, P. R. Hansen, W. J. Manning, et al. Subclinical Coronary and Aortic Atherosclerosis Detected by Magnetic Resonance Imaging in Type 1 Diabetes With and Without Diabetic Nephropathy Circulation, January 16, 2007; 115(2): 228 - 235. [Abstract] [Full Text] [PDF]